To make informed decisions about family planning, MS patients must be familiar with the latest scientific knowledge regarding MS and pregnancy. However patient surveys have revealed significant gaps in understanding around this subject [1,2].
A survey of MS patients in Denmark (n=590) found that 42% of female respondents did not know if the MS therapy they were taking had teratogenic risks . Another survey of female MS patients in Germany (n=154) also uncovered considerably low levels of knowledge regarding MS and pregnancy .
Understanding the benefits and risks of available treatments is essential for any patient who could become pregnant [2,3].
“In order to make their own independent decision based on scientific facts known to date, female MS patients need to be better informed on issues regarding MS and pregnancy" .